These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 16491284)

  • 1. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
    Land C; Rauch F; Glorieux FH
    J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.
    Rauch F; Cornibert S; Cheung M; Glorieux FH
    Bone; 2007 Apr; 40(4):821-7. PubMed ID: 17223617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.
    Munns CF; Rauch F; Travers R; Glorieux FH
    J Bone Miner Res; 2005 Jul; 20(7):1235-43. PubMed ID: 15940378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T; Bompadre V; White KK
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
    Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
    Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
    Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
    J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
    Rauch F; Travers R; Plotkin H; Glorieux FH
    J Clin Invest; 2002 Nov; 110(9):1293-9. PubMed ID: 12417568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
    Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
    J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two doses of pamidronate in infants with osteogenesis imperfecta.
    Senthilnathan S; Walker E; Bishop NJ
    Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
    Zeitlin L; Rauch F; Plotkin H; Glorieux FH
    Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
    Munns CF; Rauch F; Zeitlin L; Fassier F; Glorieux FH
    J Bone Miner Res; 2004 Nov; 19(11):1779-86. PubMed ID: 15476577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients.
    Heino TJ; Aström E; Laurencikas E; Sävendahl L; Söderhäll S
    Horm Res Paediatr; 2011; 75(5):354-61. PubMed ID: 21304249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.